{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:13:43Z","timestamp":1791530023208,"version":"4.3.4"},"reference-count":22,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute for Health and care Research Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Alcon Research Institute Young Investigator Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lister Institute for Preventive Medicine Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/T040912\/1"],"award-info":[{"award-number":["MR\/T040912\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,4,6]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Topical agents to lower intraocular pressure (IOP) are the most common initial therapeutic measure in glaucoma prevention. This study aims to assess treatment success duration among patients initiating or intensifying topical glaucoma medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records (2013\u20122018) for adults initiating\/intensifying topical glaucoma medication were extracted from five secondary-care and tertiary-care UK ophthalmology centres. Main study outcomes were time from treatment initiation\/intensification to treatment failure (&lt;20%\u2009IOP reduction or IOP &gt;21\u2009mm Hg at consecutive clinic visits, or intensification of glaucoma treatment) and time from treatment change to subsequent treatment intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Study eyes (n=6587) underwent treatment intensification 0-to-1 glaucoma drop (5358 events), 1-to-2 drops (1469 events) and 2-to-3 drops (857 events) during the observation period. Median time to treatment failure was 1.60 (95% CI 1.57 to 1.65), 1.00 (95% CI 0.94 to 1.07) and 0.92 (95% CI 0.81 to 1.02) years following escalation 0-to-1, 1-to-2 and 2-to-3 drops, respectively. Median time to treatment intensification (non-IOP\u2013based criterion) was 4.68 (95% CI 4.50 to 5.08) years for treatment initiators, 3.83 (95% CI 3.36 to 4.08) years on escalation 1-to-2 drops and 4.35 (95% CI 3.82 to 4.88) years on escalation 2-to-3 drops. On multivariable regression, significant risk factors for both treatment failure and intensification were lower baseline visual field mean deviation, primary open-angle glaucoma and lower eyedrop count in the fellow eye; lower baseline IOP was associated with treatment failure, higher baseline IOP with treatment intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Large-scale survival analyses provide the expected duration of treatment success from topical glaucoma medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2023-323708","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T13:30:19Z","timestamp":1714051819000},"page":"1701-1707","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Survival of medical treatment success in primary open-angle glaucoma and ocular hypertension"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-6912","authenticated-orcid":false,"given":"Dun Jack","family":"Fu","sequence":"first","affiliation":[{"name":"Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Ademisoye","sequence":"additional","affiliation":[{"name":"Allergan US, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Shih","sequence":"additional","affiliation":[{"name":"Allergan US, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Ian","family":"McNaught","sequence":"additional","affiliation":[{"name":"Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK"},{"name":"Plymouth University, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Khawaja","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology, London, UK"},{"name":"Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2025071603351121000_108.12.1701.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.21899"},{"key":"2025071603351121000_108.12.1701.2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"2025071603351121000_108.12.1701.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"2025071603351121000_108.12.1701.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"2025071603351121000_108.12.1701.5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"2025071603351121000_108.12.1701.6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary open-angle glaucoma preferred practice pattern(\u00ae) guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"2025071603351121000_108.12.1701.7","unstructured":"National Institute for Health and Care Excellence (Great Britain) . 2019 Exceptional Surveillance of Glaucoma: Diagnosis and Management (NICE Guideline NG81). National Institute for Health and Care Excellence (UK), 2019."},{"key":"2025071603351121000_108.12.1701.8","first-page":"S262","article-title":"Rates of discontinuation and change of glaucoma therapy in a managed care setting","volume":"8","author":"Spooner","year":"2002","journal-title":"Am J Manag Care"},{"key":"2025071603351121000_108.12.1701.9","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902791132"},{"key":"2025071603351121000_108.12.1701.10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1177\/112067210301304S02","article-title":"The Ophthalmologists of the glaucoma study. naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year","volume":"13 Suppl 4","author":"Rouland","year":"2003","journal-title":"Eur J Ophthalmol"},{"key":"2025071603351121000_108.12.1701.11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ogla.2020.09.002","article-title":"Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis","volume":"4","author":"Schwartz","year":"2021","journal-title":"Ophthalmol Glaucoma"},{"key":"2025071603351121000_108.12.1701.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.017"},{"key":"2025071603351121000_108.12.1701.13","unstructured":"[No title]. Available: https:\/\/www.researchgate.net\/profile\/Karen-Hamrick\/publication\/273447872_Time_Poverty_Thresholds_in_the_USA\/links\/5509eb0f0cf26198a639d508\/Time-Poverty-Thresholds-in-the-USA.pdf [Accessed 10 Feb 2024]."},{"key":"2025071603351121000_108.12.1701.14","unstructured":"Team RC . A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013. Available: http:\/\/www.R-project org"},{"key":"2025071603351121000_108.12.1701.15","unstructured":"Hodapp E , Parrish RK , Anderson DR . Clinical Decisions in Glaucoma. Mosby, 1993."},{"key":"2025071603351121000_108.12.1701.16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313396"},{"key":"2025071603351121000_108.12.1701.17","doi-asserted-by":"crossref","first-page":"e1589","DOI":"10.1016\/S2214-109X(21)00348-X","article-title":"Selective laser Trabeculoplasty versus 0\u00b75% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial","volume":"9","author":"Philippin","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025071603351121000_108.12.1701.18","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"2025071603351121000_108.12.1701.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0593-9"},{"key":"2025071603351121000_108.12.1701.20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/IJG.0000000000001730","article-title":"Economic and clinical burden associated with intensification of glaucoma topical therapy: A US claims-based analysis","volume":"30","author":"Patel","year":"2021","journal-title":"J Glaucoma"},{"key":"2025071603351121000_108.12.1701.21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2415-11-13","article-title":"A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with Latanoprost or Travoprost-Z monotherapy","volume":"11","author":"Fain","year":"2011","journal-title":"BMC Ophthalmol"},{"key":"2025071603351121000_108.12.1701.22","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1177\/112067210301304S04","article-title":"Clinical and economic impacts of Latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France","volume":"13 Suppl 4","author":"Bernard","year":"2003","journal-title":"Eur J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-323708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:36:41Z","timestamp":1752662201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-323708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,11,22]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bjo-2023-323708"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-323708","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}